Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12654489 | 1.00 | CA2 (0.43) | CA2CCNKCDK12MAPK14ALDH1A1 | |
| SCHEMBL16754678 | 1.00 | CA2 (0.43) | CA2CCNKCDK12MAPK14ALDH1A1 | |
| SCHEMBL29748547 | 1.00 | CA2 (0.43) | CA2CCNKCDK12MAPK14ALDH1A1 | |
| SCHEMBL29748692 | 1.00 | CA2 (0.43) | CA2CCNKCDK12MAPK14ALDH1A1 | |
| SCHEMBL17778326 | 0.87 | ALDH1A1 (0.36) | CA2CCNKCDK12MAPK14ALDH1A1 | |
| SCHEMBL17778616 | 0.87 | ALDH1A1 (0.36) | CA2CCNKCDK12MAPK14ALDH1A1 | |
| SCHEMBL30781617 | 0.85 | CCNK (0.42) | CA2CCNKCDK12MAPK14ALDH1A1 | |
| SCHEMBL17768163 | 0.83 | NUDT1 (0.44) | CA2CCNKCDK12MAPK14ALDH1A1 | |
| SCHEMBL14881706 | 0.83 | NUDT1 (0.44) | CA2CCNKCDK12MAPK14ALDH1A1 | |
| SCHEMBL17768221 | 0.83 | NUDT1 (0.44) | CA2CCNKCDK12MAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4230618-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230618-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| CN-114031518-B | Benzylamine or benzyl alcohol derivative and application thereof | 成都海博为药业有限公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2022121517-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | 成都海博为药业有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022121517-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | 成都海博为药业有限公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-114031518-A | Benzylamine or benzyl alcohol derivative and application thereof | 成都海博为药业有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | disclosed |
| WO-2016079709-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079711-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079712-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079710-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079712-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016081692-A2 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079709-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CA2 4253/4885CCNK 1153/4885CDK12 1089/4885 |
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | SCN8A, SCN9A, SCN10A | CA2 2399/4885CCNK 3859/4885CDK12 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.